enGene Therapeutics (ENGN) Return on Equity [ROE] (2024 - 2026)
enGene Therapeutics (ENGN) recorded Return on Equity [ROE] of -53.71% in fiscal Q3 2026 (quarter ended Jul 31, 2026), down 9.44 percentage points from -44.27% a year earlier and down 6.44 percentage points from the prior quarter.
Powered by 
Analysis
enGene Therapeutics (ENGN) Return on Equity [ROE] (2024 - 2026) Analysis & Trends
For FY2025 (ended Oct 31, 2025), enGene Therapeutics reported Return on Equity [ROE] of -53.28%, down 21.32 percentage points from FY2024.
- Across earlier fiscal years, Return on Equity [ROE] came in at -31.96% in FY2024.
- Quarterly Return on Equity [ROE] has ranged from -153.05% in fiscal Q1 2024 to -21.93% in fiscal Q4 2024 over the past five years.
- On a year-over-year basis, Return on Equity [ROE] has declined for four consecutive quarters, with an average year-over-year change of +11.64 percentage points over the last seven quarters.
- Per Business Quant, the preceding three fiscal quarters came in at -47.27% (Q2 2026), -54.51% (Q1 2026) and -63.68% (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | - |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 84.40% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.97% |
| 10 | enGene Therapeutics | 130.01 Mn | 130.01 Mn | - | -53.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | -53.71% |
| Apr 30, 2026 | -47.27% |
| Jan 31, 2026 | -54.51% |
| Oct 31, 2025 | -63.68% |
| Jul 31, 2025 | -44.27% |
| Apr 30, 2025 | -33.47% |
| Jan 31, 2025 | -26.43% |
| Oct 31, 2024 | -21.93% |
| Jul 31, 2024 | -51.70% |
| Apr 30, 2024 | -73.96% |
| Jan 31, 2024 | -153.05% |
API Access
enGene Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=ENGN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "ENGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=ENGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();